EA024557B1 - Способы введения соединений, являющихся агонистами тромбопоэтина - Google Patents
Способы введения соединений, являющихся агонистами тромбопоэтина Download PDFInfo
- Publication number
- EA024557B1 EA024557B1 EA201171462A EA201171462A EA024557B1 EA 024557 B1 EA024557 B1 EA 024557B1 EA 201171462 A EA201171462 A EA 201171462A EA 201171462 A EA201171462 A EA 201171462A EA 024557 B1 EA024557 B1 EA 024557B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- dose
- administration
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims description 91
- 229940123936 Thrombopoietin agonist Drugs 0.000 title 1
- 206010043554 thrombocytopenia Diseases 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000012423 maintenance Methods 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 42
- -1 3,4-dimethylphenyl Chemical group 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 17
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 abstract description 13
- 208000004235 neutropenia Diseases 0.000 abstract description 6
- 210000005259 peripheral blood Anatomy 0.000 abstract description 6
- 239000011886 peripheral blood Substances 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 56
- 108010041111 Thrombopoietin Proteins 0.000 description 56
- 229940126062 Compound A Drugs 0.000 description 33
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 33
- 238000011282 treatment Methods 0.000 description 28
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 13
- 238000011269 treatment regimen Methods 0.000 description 12
- 229940126214 compound 3 Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000003593 megakaryocyte Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 description 2
- 229960001069 eltrombopag Drugs 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000003582 thrombocytopenic effect Effects 0.000 description 2
- OCZVWZVTEQXRPI-UHFFFAOYSA-N 3-(2-hydroxyphenyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 OCZVWZVTEQXRPI-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000246838 Falcataria moluccana Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700022598 Ovis aries megapoietin Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000002299 complementary DNA Chemical group 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 102000054764 human MPL Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18214809P | 2009-05-29 | 2009-05-29 | |
| PCT/US2010/036294 WO2010138656A1 (en) | 2009-05-29 | 2010-05-27 | Methods of administration of thrombopoietin agonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201171462A1 EA201171462A1 (ru) | 2012-05-30 |
| EA024557B1 true EA024557B1 (ru) | 2016-09-30 |
Family
ID=43223061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690401A EA201690401A1 (ru) | 2009-05-29 | 2010-05-27 | Способы введения соединений, являющихся агонистами тромбопоэтина |
| EA201171462A EA024557B1 (ru) | 2009-05-29 | 2010-05-27 | Способы введения соединений, являющихся агонистами тромбопоэтина |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690401A EA201690401A1 (ru) | 2009-05-29 | 2010-05-27 | Способы введения соединений, являющихся агонистами тромбопоэтина |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8609693B2 (enExample) |
| EP (2) | EP3127427B1 (enExample) |
| JP (3) | JP2012528184A (enExample) |
| KR (1) | KR20120015355A (enExample) |
| CN (2) | CN102458120A (enExample) |
| AU (1) | AU2010254046C1 (enExample) |
| BR (1) | BRPI1014548A2 (enExample) |
| CA (1) | CA2763768A1 (enExample) |
| DK (1) | DK3127427T3 (enExample) |
| EA (2) | EA201690401A1 (enExample) |
| ES (2) | ES2782898T3 (enExample) |
| HU (1) | HUE049075T2 (enExample) |
| IL (1) | IL216365A (enExample) |
| MX (1) | MX2011012668A (enExample) |
| PL (2) | PL2434894T3 (enExample) |
| PT (2) | PT3127427T (enExample) |
| SG (1) | SG176088A1 (enExample) |
| SI (1) | SI3127427T1 (enExample) |
| WO (1) | WO2010138656A1 (enExample) |
| ZA (1) | ZA201108374B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120149749A1 (en) * | 2008-10-16 | 2012-06-14 | Michael Arning | Method of treating thrombocytopenia |
| JP2012528184A (ja) | 2009-05-29 | 2012-11-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | トロンボポエチンアゴニスト化合物の投与の方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089457A2 (en) * | 2000-05-25 | 2001-11-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2008136843A1 (en) * | 2007-05-03 | 2008-11-13 | Smithkline Beecham Corporation | Novel pharmaceutical composition |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE193350C (enExample) | ||||
| US851444A (en) | 1905-11-13 | 1907-04-23 | Agfa Ag | Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same. |
| GB779880A (en) | 1953-02-27 | 1957-07-24 | Ciba Ltd | Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them |
| US2809963A (en) | 1954-10-26 | 1957-10-15 | Ciba Ltd | Azo-dyestuffs |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| GB826207A (en) | 1956-07-23 | 1959-12-31 | Bayer Ag | ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds |
| US2950273A (en) | 1956-11-20 | 1960-08-23 | Agfa Ag | Process for the production of symmetrical and unsymmetrical azo compounds |
| US3366619A (en) | 1965-04-09 | 1968-01-30 | Interchem Corp | Disazo pyrazolone pigments |
| US4435417A (en) | 1981-02-20 | 1984-03-06 | Gruppo Lepetit S.P.A. | Antiinflammatory 3H-naphtho[1,2-d]imidazoles |
| ES523609A0 (es) | 1982-07-05 | 1985-03-01 | Erba Farmitalia | Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos. |
| FR2559483B1 (fr) | 1984-02-10 | 1986-12-05 | Sandoz Sa | Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants |
| US4582831A (en) | 1984-11-16 | 1986-04-15 | Pfizer Inc. | Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor |
| FI91869C (fi) | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| US4880788A (en) | 1987-10-30 | 1989-11-14 | Baylor College Of Medicine | Method for preventing and treating thrombosis |
| WO1993017681A1 (en) | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| IL109570A0 (en) | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| EP0638617A1 (de) | 1993-08-13 | 1995-02-15 | Ciba-Geigy Ag | Pigmentsalze |
| EP0854052B1 (en) | 1993-12-28 | 2000-03-22 | Dai Nippon Printing Co., Ltd. | Thermal-transfer recording sheet using a specific dye |
| US5482546A (en) | 1994-03-30 | 1996-01-09 | Canon Kabushiki Kaisha | Dye, ink containing the same, and ink-jet recording method and instrument using the ink |
| HU218893B (hu) | 1994-03-31 | 2000-12-28 | Amgen Inc. | A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények |
| US5760038A (en) | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5746821A (en) | 1995-02-13 | 1998-05-05 | Engelhard Corporation | Pigment compositions |
| CZ291749B6 (cs) | 1995-06-07 | 2003-05-14 | Glaxo Group Limited | Peptidová sloučenina, která se váže na thrombopoetinový receptor a aktivuje jej a farmaceutický prostředek |
| US5622818A (en) | 1995-11-29 | 1997-04-22 | Eastman Kodak Company | Color photographic elements containing yellow colored magenta dye forming masking couplers |
| US5669967A (en) | 1996-05-30 | 1997-09-23 | Engelhard Corporation | Pigment compositions |
| US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| GB9715830D0 (en) | 1997-07-25 | 1997-10-01 | Basf Ag | Reactive dyes containing piperazine |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE69837279T2 (de) | 1997-10-31 | 2007-11-15 | Smithkline Beecham Corp. | Neue metall-komplexe |
| DE19851389A1 (de) | 1998-11-07 | 2000-05-11 | Dystar Textilfarben Gmbh & Co | Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| CO5210907A1 (es) | 1999-05-12 | 2002-10-30 | Novartis Ag | Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones |
| WO2001007423A1 (en) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
| ES2256038T3 (es) | 1999-09-10 | 2006-07-16 | Smithkline Beecham Corporation | Mimeticos de trombopoyetina. |
| JP2003509462A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | トロンボポイエチン模倣物 |
| AU1462201A (en) | 1999-11-05 | 2001-06-06 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| EP1104674A1 (de) | 1999-11-10 | 2001-06-06 | Curacyte AG | O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| HUP0001417A2 (hu) | 2000-04-07 | 2002-12-28 | Sanofi-Synthelabo | Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények |
| US6436915B1 (en) | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| US6214813B1 (en) | 2000-04-07 | 2001-04-10 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| AU2002239718A1 (en) | 2000-12-19 | 2002-07-01 | Ligand Pharmaceuticals | Thrombopoietin mimetics |
| WO2002057300A1 (en) | 2000-12-21 | 2002-07-25 | Smithkline Beecham Corporation | Regulated activation of cell-membrane receptors by metal-chelating agonists |
| EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
| JP4145655B2 (ja) | 2001-01-26 | 2008-09-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物 |
| WO2002085343A1 (en) | 2001-03-01 | 2002-10-31 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| JP3927001B2 (ja) | 2001-06-15 | 2007-06-06 | 三菱化学株式会社 | 色素セット、インクセット並びに記録方法 |
| MXPA04005204A (es) | 2001-11-30 | 2005-11-04 | Quadra Logic Tech Inc | Derivados de hidrazonipirazol y su uso como terpapeuticos. |
| AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| TWI280128B (en) | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| JP4562523B2 (ja) | 2002-06-06 | 2010-10-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | トロンボポエチン疑似体 |
| WO2004029049A1 (ja) | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
| EP1581527A4 (en) | 2002-12-13 | 2006-11-22 | Smithkline Beecham Corp | MIMETICS OF THROMBOPOIETINE |
| WO2004096154A2 (en) | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
| TW200526638A (en) | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| WO2007028106A2 (en) * | 2005-08-31 | 2007-03-08 | Centocor, Inc. | Host cell lines for production of antibody constant region with enhanced effector function |
| US20070202140A1 (en) * | 2005-12-22 | 2007-08-30 | Veltri Enrico P | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
| WO2008073864A1 (en) | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Novel combinations |
| UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| WO2009151862A1 (en) | 2008-05-15 | 2009-12-17 | Smithkline Beecham Corporation | Method of treatment |
| US20120149749A1 (en) | 2008-10-16 | 2012-06-14 | Michael Arning | Method of treating thrombocytopenia |
| WO2010129738A1 (en) | 2009-05-07 | 2010-11-11 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
| JP2012528184A (ja) | 2009-05-29 | 2012-11-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | トロンボポエチンアゴニスト化合物の投与の方法 |
| JP6999080B2 (ja) | 2015-04-11 | 2022-02-04 | 株式会社アーティエンス・ラボ | 画像認識システム、画像認識方法、ホログラム記録媒体、ホログラム再生装置および画像撮影装置 |
-
2010
- 2010-05-27 JP JP2012513237A patent/JP2012528184A/ja not_active Withdrawn
- 2010-05-27 KR KR1020117031236A patent/KR20120015355A/ko not_active Ceased
- 2010-05-27 ES ES16183711T patent/ES2782898T3/es active Active
- 2010-05-27 PT PT161837117T patent/PT3127427T/pt unknown
- 2010-05-27 EP EP16183711.7A patent/EP3127427B1/en not_active Revoked
- 2010-05-27 CN CN2010800335467A patent/CN102458120A/zh active Pending
- 2010-05-27 EP EP10781176.2A patent/EP2434894B1/en active Active
- 2010-05-27 CA CA2763768A patent/CA2763768A1/en not_active Abandoned
- 2010-05-27 BR BRPI1014548-6A patent/BRPI1014548A2/pt not_active Application Discontinuation
- 2010-05-27 SI SI201031994T patent/SI3127427T1/sl unknown
- 2010-05-27 WO PCT/US2010/036294 patent/WO2010138656A1/en not_active Ceased
- 2010-05-27 EA EA201690401A patent/EA201690401A1/ru unknown
- 2010-05-27 SG SG2011084191A patent/SG176088A1/en unknown
- 2010-05-27 PL PL10781176T patent/PL2434894T3/pl unknown
- 2010-05-27 PL PL16183711T patent/PL3127427T3/pl unknown
- 2010-05-27 DK DK16183711.7T patent/DK3127427T3/da active
- 2010-05-27 CN CN201410340066.5A patent/CN104173337A/zh active Pending
- 2010-05-27 US US13/321,577 patent/US8609693B2/en active Active
- 2010-05-27 PT PT107811762T patent/PT2434894T/pt unknown
- 2010-05-27 HU HUE16183711A patent/HUE049075T2/hu unknown
- 2010-05-27 MX MX2011012668A patent/MX2011012668A/es active IP Right Grant
- 2010-05-27 ES ES10781176.2T patent/ES2605593T3/es active Active
- 2010-05-27 AU AU2010254046A patent/AU2010254046C1/en not_active Ceased
- 2010-05-27 EA EA201171462A patent/EA024557B1/ru not_active IP Right Cessation
-
2011
- 2011-11-14 IL IL216365A patent/IL216365A/en not_active IP Right Cessation
- 2011-11-15 ZA ZA2011/08374A patent/ZA201108374B/en unknown
-
2015
- 2015-08-10 JP JP2015158039A patent/JP2016020360A/ja not_active Withdrawn
-
2017
- 2017-07-06 JP JP2017132914A patent/JP2017226668A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089457A2 (en) * | 2000-05-25 | 2001-11-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2008136843A1 (en) * | 2007-05-03 | 2008-11-13 | Smithkline Beecham Corporation | Novel pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| RXLIST. Promacta Drug Description. 15 January 2009 (15.01.2009), p. 1-12 [online article]; document retrieved on 08 July 2010, [retrieved from http://www.rxlist.com/promacta-drug.htm]; especially, pg. 1, para 4; pg. 2, para 1, 6, 9; pg. 12, para 4. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105705148B (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| RU2508116C2 (ru) | Способ и композиции для лечения рака | |
| EA022166B1 (ru) | Синтетические тритерпеноиды и их применение в лечении заболеваний | |
| CA2859940A1 (en) | Method for administration of an anti tumor agent | |
| CN116867505A (zh) | 替西帕肽治疗方法 | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| EA024557B1 (ru) | Способы введения соединений, являющихся агонистами тромбопоэтина | |
| US20160199350A1 (en) | Combination of hdac inhibitors with thrombocytopenia drugs | |
| RU2664442C2 (ru) | Способ снижения веса | |
| AU2019379782A1 (en) | Combination of a Mcl-1 inhibitor and Midostaurin, uses and pharmaceutical compositions thereof | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
| CA3119395C (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| RU2341254C1 (ru) | Стабильная фармацевтическая композиция, обладающая антигипертензивным действием | |
| CN118059105A (zh) | 一种降血压的药物组合物 | |
| AU2024259627A1 (en) | Methods of treating hepatic-only metastatic uveal melanoma | |
| RU2561583C2 (ru) | Фармацевтическая композиция для лечения и/или предупреждения нарушений, связанных с ожирением, и способ лечения и/или предупреждения нарушений, связанных с ожирением | |
| TW202529797A (zh) | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 | |
| CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
| WO2021202259A2 (en) | Fibrillation resistant calcitonin peptides and uses thereof | |
| EA028400B1 (ru) | Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений | |
| Gonyeau et al. | Should gabapentin be dose adjusted: What are the clinical consequences? | |
| CN108236611A (zh) | 两种化合物联合在制备治疗糖尿病药物中的用途 | |
| EA022732B1 (ru) | Фармацевтическая композиция и набор для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением | |
| CN105777744A (zh) | 一种降血糖的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |